In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hologic Inc.

www.hologic.com

Latest From Hologic Inc.

Market Intel: Precision Diagnostics And Focal Treatments Offer Personalized Approach To Prostate Cancer

The combined market for prostate cancer diagnostics and minimally invasive treatments is set to increase from $900m to $1.46bn in the next five years. But conservative treatment, or watchful waiting, is popular, limiting growth of newer, focal treatments.

Market Intelligence Cancer

Survey Finds 1/3 Of Device Firms Don't Measure The Cost Of Quality. Here's How A Case For Quality Initiative Might Help

A recent device industry survey shows that 33% of manufacturers are likely wasting money on quality efforts that are ineffective because they're not calculating the cost of quality. The survey comes under the auspices of a Case for Quality workgroup that is looking for best ways to engage leadership at device firms in quality activities. The group says it will use the survey results to inform its work as it pens a playbook of best practices for engaging leaders that will, among other things, stress the importance of knowing the cost of quality.

Quality Trends

Market Brief: The Global Market For Prostate Cancer Diagnostics Will Reach $460.5M In 2023

The global market for prostate cancer diagnostics is expected to see double-digit growth, reaching $460.5m in 2023 and is driven by new technologies, in particular liquid biopsies and new genetic marker tests, according to a new report by Informa's Meddevicetracker.

Innovation Market Intelligence

FDA Approves Channel Medystems’ Cerene Endometrial Cryotherapy

Cerene is indicated for endometrial cryoablation in premenopausal women. Channel's PMA is based on 12-month results from the CLARITY trial, which showed procedural success with Cerene in about 77% of patients.

Commercial Approvals
See All

Company Information

UsernamePublicRestriction

Register